

GLOBAL WELLNESS



GUFIC
BIOSCIENCES LIMITED

28TH ANNUAL REPORT 2011-2012

BOARD OF DIRECTORS

Mr. Jayesh P. Choksi	(Chairman & Managing Director)
Mr. Pranav J. Choksi	(Executive Whole time Director)
Dr. M. G. Dhapalapur	(Executive Whole time Director)
Mr. Sharat S. Gandhi	(Non-executive Independent Director)
Mr. Ashok M. Tarale	(Non-executive Independent Director)
Mr. Khantilal N. Sanghavi	(Non-executive Independent Director)

COMPANY SECRETARY AND COMPLIANCE OFFICER

Mr. Prakash Khulbe

AUDITOR

Mayur Chokshi & Co
Chartered Accountants, Ground Floor, Tibrewala House,
33, Swastik Society, N.S. Road No 3, JVPD Scheme, Mumbai – 400 056

BANKERS

State Bank Of India
ICICI Bank
Corporation Bank
Bank of Baroda

REGISTERED OFFICE ADDRESS

Subhash Road – A,
Vile Parle (E),
Mumbai – 400 057.

ADMINISTRATIVE OFFICE

Old Sanskar Jyot School Bldg.
2nd & 3rd Floor, (Above Bank Of Maharashtra)
S.V. Road, Andheri (W), Mumbai - 400 058.
Tel.: 91- 22- 67261000. Email : gufic@guficbio.com
Website : www.guficbio.com

PLANT

National Highway No. 8, Near Grid,
Kabilpore Navsari, Gujarat 396 424
Tel.: 91 - 02637 - 239946 / 329424

REGISTRAR AND TRANSFER AGENTS

LINK INTIME INDIA PVT. LTD.
C – 13, Pannalal Silk Mills Compound,
L.B.S. Road, Bhandup (W) , Mumbai 400 078.
Tel No.: (022) 2594 6970
Fax (022) 2594 6969
Email: rnt.helpdesk@linkintime.co.in

28th Annual General Meeting

DAY & DATE

Friday, 24th August, 2012

TIME

2.30 PM.

VENUE

Hotel Parle International,
B. N. Agarwal Market,
Next to Dinanath Mangeshkar Hall,
Vile Parle (E), Mumbai - 400 057.

Contents

Page No.

Chairman's Message	1
Directors' Report	2
Management Discussion & Analysis Report	5
Corporate Governance Report	8
Auditors' Report on Corporate Governance	16
Auditors' Report	17
Annexure to Auditors' Report	19
Balance Sheet	21
Profit & Loss Statement	22
Cash Flow	23
Notes to the Financial Statements	24

GUFIC BIOSCIENCES LIMITED

Chairman's Message



Dear Shareholder,

During the year, Gufic registered a growth of 17.18 % in sales, despite the year being full of challenges. Economic slowdown, rising inflation and depreciation of rupee against the dollar, were the major challenges that the industry faced. It is widely envisaged that the global economy will face tough times if the Euro zone crisis is not resolved. On the Indian economic front, several reforms and policy initiatives are expected to put the growth engine back on track.

The domestic business registered a growth of 11.0 % at ₹ 3575.0 million as against ₹ 3219.6 million last year.

Gufic has a strong and dedicated sales network of 500 field staff covering 125000 doctors, 20 C&Fs, 1000 stockists & 300000 Retailers. Gufic has its presence throughout the length and breadth of the country. Through Gufic Stridden Biopharma Private Limited, export subsidiary of Gufic Biosciences Limited., we have started submitting 66 dossiers in 21 countries.

We have launched Relieve & Relax product in the consumer segment and initially this product is getting good response from the consumers.

Gufic has been the pioneer in technology of Lyophilization. Currently we have evolved as a leader in India and have 6 Lyophilizers catering to total capacity of 14.4 million vials per annum.

Gufic has world class manufacturing plants at 4 locations with 500 workforce with WHO GMP approved manufacturing facility.

As you are aware that Gufic operates in 3 segments namely (1) Formulation Division (2) Bulk Drug Division and (3) Consumer Product Division. The Company's main focus is on Formulation Division which has achieved a growth rate of more than 34% in sales from ₹ 507.01 million in fiscal year 2010-2011 to ₹ 680.75 million in the fiscal year 2011-2012. Growth of Bulk Drug Division has lowered by 12.75% from ₹ 130.64 million in fiscal year 2010-2011 to ₹ 113.98 million in the fiscal year 2011-2012. Due to change in governmental policies and increase in rates of taxation, our Consumer Product Division sales have come down considerably in last 2 years or so. Sales are lowered by 32% from ₹ 99.23 million in fiscal year 2010-2011 to ₹ 67.38 million in fiscal year 2011-2012.

We re-affirm our assurance to all our stakeholders of adhering to our core values which are inline with Gufic's vision and mission.

I would like to express my gratitude to all our stakeholders including shareholders, customers, bankers, vendors and the medical fraternity for their unstinted support. I thank all the Guficians for their contribution towards Gufic's success.

Yours truly,
For Gufic Biosciences Limited



Jayesh P. Choksi
Chairman & Managing Director

DIRECTORS' REPORT

The Members,

Your Directors have pleasure in presenting the Twenty Eighth Annual Report of the Company, together with the Audited Accounts for the financial year ended 31st March, 2012.

FINANCIAL SUMMARY:

₹ in Lacs

Particulars	2011-12	2010-11
Total Revenues	8393.28	7162.77
Profit Before Interest, Depreciation and Tax (PBIDT)	748.20	608.28
Interest	263.07	190.58
Depreciation	188.12	180.66
Profit Before Tax (PBT)	296.01	237.04
Provision for Tax	125.50	60.41
Excess Provisions Written Back	29.18	1.69
Provision for Deferred Taxation	(10.38)	28.54
Profit After Tax (PAT)	152.71	146.40
Surplus Brought Forward	922.95	821.65
Balance Available for Appropriation	1075.66	968.05
Appropriations:		
Dividend	38.68	38.68
Tax on Dividend	6.27	6.42
Transfer to General Res.	—	--
Surplus Carried Forward	1030.71	922.95

FINANCIAL HIGHLIGHTS:

During the year under review the sales increased to ₹ 8393.28 Lacs in comparison to previous year's ₹ 7162.77 Lacs an increased of 17.18%. PBIDT increased by 23% and PBT increased by 25.30%. PAT increased by 4.30%.

DIVIDEND:

The Directors are pleased to recommend a Dividend of 5 % per equity share of ₹.1 each for the financial year ended 31st March 2012.

LISTING:

Your Company is listed with the Bombay Stock Exchange Limited at P. J. Towers, Dalal Street, Mumbai 400 001, bearing Scrip Code No. 509079 and with the National Stock Exchange of India Limited at Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 bearing Scrip Code GUFICBIO. The listing fees for the year 2012- 2013 has already been paid by the Company.

FIXED DEPOSITS:

During the year under review, your Company has not accepted any deposits from the public.

GUFIC BIOSCIENCES LIMITED

DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of provisions of Section 217(2AA) of the Companies Act, your Directors' confirm that:

- In the preparation of the annual accounts, the applicable accounting standards have been followed;
- Appropriate accounting policies have been selected and applied consistently and judgments and estimates made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year ended 31st March, 2012 and of the profits of the Company for that period;
- Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- The annual accounts have been prepared on a going concern basis.

CORPORATE GOVERNANCE REPORT AND MANAGEMENT DISCUSSION AND ANALYSIS REPORT

A Report on Corporate Governance along with a Certificate from the Auditors of the Company regarding compliances with the conditions of Corporate Governance pursuant to Clause 49 of the Listing Agreement is annexed hereto.

Management Discussion and Analysis Report, as required under the Listing Agreements with the Stock Exchanges is given as a separate statement, which forms part of this Annual Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGOES:

The information required under Section 217(1) (e) of the Companies Act, 1956 read with the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988 is annexed hereto and forms part of this Report.

PARTICULARS OF EMPLOYEES:

There are no employees whose information is required to be given under Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975 as amended.

DIRECTORS:

As per the provisions of Companies Act, 1956 and Articles of Association, Mr. Sharat S. Gandhi and Mr. Pranav J. Choksi retires by rotation at the ensuing Annual General Meeting and being eligible offers themselves for reappointment.

AUDITORS:

Comments given by the Auditors in their Audit Report when read together with the notes to Accounts are self explanatory and needs no further comments.

APPRECIATION:

Your Directors wish to place on record their sincere appreciation for the continuous support received from your Company's customers, its dealers and suppliers and from its bankers. Your directors also acknowledge with gratitude the encouragement and support extended by its valued shareholders.

For and on behalf of the Board of Directors,

Place: Mumbai
Date: 10th July, 2012

Jayesh Choksi
Chairman & Managing Director

CONSERVATION AND CONSUMPTION OF ENERGY, FOR FOREIGN EXCHANGE EARNINGS AND OUTGO

I. (A) CONSERVATION OF ENERGY

Details of conservation of energy are as follows:

Power & Fuel Consumption

		Year ended 31.03.12	Year ended 31.03.11
(a) Electricity			
Purchased Units	Kwh	2259182	2103803
Total amount	₹ in Lacs	136.47	121.25
Rate per unit (average)	₹	6.04	5.76
(b) Furnace Oil			
Quantity	Ltrs.	258444	262218
Total Cost	₹ in Lacs	92.52	73.01
Average Cost	₹	35.80	27.84

(B) CONSUMPTION PER UNIT OF PRODUCTION

Since the Company manufactures several formulations and bulk drugs in the same factory it is not practical to Apportion consumption of Electricity and Furnace Oil to unit of Product.

II. FOREIGN EXCHANGE EARNINGS AND OUTGO

Foreign Exchange earning amounted to ₹ 871.38 Lacs and for the previous year it was ₹ 1141.67 Lacs and the total foreign exchange outgo amounted to ₹ 352.78 Lacs and for the previous year it was ₹ 373.89 Lacs.

For and on behalf of the Board of Directors

Jayesh.P. Choksi
Chairman & Managing Director
Mumbai : 10th July, 2012

MANAGEMENT DISCUSSION & ANALYSIS REPORT:

GLOBAL PHARMACEUTICAL MARKET

The world pharmaceutical market for 2011-12 was around USD 900 billion registering a growth of around 4-5%. Average revenue growth in established markets was around 3% while that in emerging markets was around 12%. The top five pharmaceutical markets in the world remained the US, Japan, Germany, France and China with the US representing 38.1% of global prescription pharmaceutical sales. For 2012-13, the estimated value of Pharmaceutical market is USD 920-950 billion giving an expected growth rate of around 3-5%.

INDIAN PHARMACEUTICAL MARKET

India ranks 10th globally in terms of value and 3rd in terms of volumes. Indian pharmaceutical market is dominated majorly by branded generics constituting nearly 70% to 80% (Source: IMS India Pharma Report) of market. Indian formulations market is currently valued at ` 555 billion and has grown at a CAGR of 15% (Source: ORG - IMS) over last 5 years.

Growing population, improving medical infrastructure, rising income levels, increasing health insurance coverage and increasing government spend on healthcare are driving the market growth. Indian market is witnessing gradual transition from acute diseases to lifestyle diseases and chronic therapies like Cardiology, Neurology, Psychiatry and Diabetes. With current demographic profile and growth prospects of the economy, Indian Pharmaceutical market could see continuing trend of transition towards chronic and super specialty therapies, with acute therapies retaining their market size.

Indian Pharma market is also witnessing shift of focus from Metro's and Tier I cities to rural areas. Currently Metro's and Tier I cities contribute majority to Indian formulations market which is growing at 15% p.a. Higher penetration, increasing per capita income and increased focus of Pharma companies into rural and Tier II to Tier VI markets is expected to out pace growth of these geographies compared to Metros and Tier I cities.

Over the coming years, patent laws will provide an impetus to the launch of patent protected products. The market for patented products is likely to be concentrated in therapeutic segments like Neuro-Psychiatry, Oncology, Anti-Infective, Gastro-Intestinal, and Cardiovascular. Such products have the potential to capture 10% of the overall market in the coming years.

India is one of the largest branded generic markets across globe primarily because of high influence of physicians in the country. This picture is distinctly different from other larger generics markets like US with balance of power entirely in favour of the trade.

Outlook for generics in India looks positive due to several factors. The current pipeline of the generics products that are either undergoing new process development or have been recently launched is strong. In addition, domestic players have the opportunity to develop new combinations and formulations of the products that are already in the market. Generics players continue to have a wide range of options for new generics launches from the basket of pre 1995 products. Currently, the prices of 74 drugs are controlled as per the mandate issued by the Drug Price Control Order, 1995 (DPCO). Currently 10% of company's revenues are from products covered by DPCO.

Given the above developments, companies need to focus on brand building and customize marketing approach to suit different customer segments. Medium term growth would be driven by therapy expansion and new product introductions.

INCREASING CONSUMPTION OF MEDICINES IN INDIA:

Indian Pharmaceutical Market (IPM) continued to grow at a scorching pace of around 15% registering a turnover of Rs 59,621 Crore during the year. (Source: Nov 2011 - AIOCD/AWACS).

Fast increasing consumption of medicines in the country continued to position IPM not just as another global success story, but also an emerging pharmaceutical force to reckon with, especially in the development and manufacturing of high quality and low cost generic pharmaceuticals together with its world-class Contract Research and Manufacturing Services (CRAMS). Indian pharmaceutical players now cater to about 20% of global requirements of high quality and affordable generic medicines of all types.

Like many other sectors, the pharmaceutical industry of India also witnessed the reform oriented policy paralysis of the government in 2011, barring some superficial, half-hearted and incomplete initiatives, as indicated above.


Key areas of general public health interest, encouraging innovation, fostering R&D and improving access to medicines to alleviate healthcare related problems of the common man and at the same time to propel the industry to the inclusive high growth trajectory, have still remained unanswered.

Faster recovery from reform-oriented policy paralysis of the government and effective translation into reality of the seemingly good intent of the policy makers, is now eagerly awaited in 2012-13


COMPANY PERFORMANCE

Highlights of financial year ended 2011-12




- Total revenues of the Company increased by 17.18%
- Sales of Formulation Division increased by over 34%
- Sales of Bulk Drug Division lowered by 12.75%
- Sales of Consumer Division lowered by 32%



SEGMENT WISE PERFORMANCE



Sales		₹ in Lacs		
Segment	2011-12	2010-11	2009-10	
Pharma				
A. Formulation	6807.51	5070.17	3919.99	
B. Bulk Drugs	1139.81	1306.36	1216.00	
Consumer	673.82	992.34	1129.33	
Agro Products	--	--	136.25	
Total	8621.14	7368.87	6401.56	



GUFIC BIOSCIENCES LIMITED

Human Resources Development



The backbone of any successful company is the HR department, and without a talented group of people to hire, culture, and inform employees, the company is doomed for failure.

The main role of HR is to act as a liaison between the management and workforce of the organization

Human resources are important to organizations in various areas, ranging from strategic planning to company image. HR in business who has well-rounded expertise provides a number of services to employees. The areas in which HR maintains control can enhance employees' perception of HR throughout the workforce when they believe HR considers employees to be its internal customers and renders services with that in mind.

HR improves the company's bottom line with its knowledge of how human capital affects organizational success. Leaders with expertise in HR strategic management participate in corporate decision-making that underlies current staffing assessments and projections for future workforce needs based on business demand.

In Gufic, Human Resource Department operates in 10 specific areas i.e.

1. **Strategy:** HR improves the company's bottom line with its knowledge of how human capital affects organizational success.
2. **Benefits:** HR can reduce the company's costs associated with turnover, attrition and hiring replacement workers.
3. **Safety:** HR engages employees in promoting awareness and safe handling of dangerous equipment and hazardous chemicals.
4. **Liability:** HR employees minimize the organization's exposure and liability related to allegations of unfair employment practices.
5. **Training and Development:** HR specialists coordinate new employee orientation, an essential step in forging a strong employer-employee relationship.
6. **Employee Satisfaction:** HR Employees help the organization achieve high performance, morale and satisfaction levels throughout the workforce, by creating ways to strengthen the employer-employee relationship.
7. **Recruitment:** HR recruiters manage the employment process from screening resumes to scheduling interviews to processing new employees.
8. **Selection:** HR professionals work closely with hiring managers / employees / workers to effect good hiring decisions, according to the organization's workforce needs.
9. **Compensation:** HR specialists develop realistic compensation structures that set company wages competitive with other businesses in the area, in the same industry or companies competing for employees with similar skills.
10. **Compliance:** HR ensures that the organization complies with all applicable laws relating to work force under PF ESIC Gratuity etc. They complete necessary paperwork and documentation so that the company's employees and their family members receive all the benefits that the employee is entitled to, under various laws.

Human Resource development continues to be a key focus area at Gufic and your Company takes great pride in the commitment, competence and vigor shown by its workforce in all realms of business.

Internal Control System

Integrated system of communication, control and reporting has given all requisite tools to the Management to manage effectively and efficiently. Internal controls are designed to ensure compliance with policies of the company, to comply with statutory requirements, to prevent any fraud or misuse of the resources and to protect shareholders' interest. Electronic internal control system, internal audit system has made possible to effectively manage stocks placed at the C & F agent and at the factory premises of the company.

Disclaimer

This Annual Report has been prepared for the members of the Company and no one else. The Company, its Directors, employees or agents do not accept or assume responsibility to any other person in connection with this document and any such responsibility or liability is expressly disclaimed. This Annual Report contains certain forward-looking statements. By their nature, these statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. The forward-looking statements reflect the knowledge and information available at the date of preparation of this Annual Report, and will not be updated during the year. Nothing in this Annual Report should be construed as a profit forecast.

CORPORATE GOVERNANCE REPORT

Corporate Governance and practices in accordance with the provisions of the Revised Clause 49 of the Listing Agreement:

THE COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

The Company's philosophy on corporate governance enshrines the goal of achieving the highest levels of transparency, accountability and equity in all spheres of its operations and in all its dealing with the shareholders, employees, the government and other parties. The company believes in the philosophy on code of corporate governance, which provides a structure by which the rights and responsibility of different constituents, such as the board, employees and shareholders are carved out. In carrying out this, it is ensured that the Company's objectives are well defined and performance against those objectives are adequately measured and monitored.

Corporate governance is considered as an important tool for shareholders protection and maximization of their long-term values. The cardinal principal such as accountability, responsibility, transparency and fair disclosure serve as the means for achieving this.

I. BOARD OF DIRECTORS:

(A) Composition and size of the Board

The Board of Directors comprises of Six (6) Directors. The Board has an optimum combination of 3 Executive and 3 Non-Executive Directors. The Chairman is an Executive Non-Independent Director and 3 Non-Executive Directors on the Board are holding Directorship in Independent capacity.

(B) Non executive directors' compensation and disclosures

No fees/compensation is paid to non-executive directors, including independent directors, which requires previous approval of shareholders in general meeting.

The Non-Executive Directors are entitled to payment of sitting fees only made within the limits prescribed under the Companies Act, 1956 without approval of the Central Government.

(C) Provisions as to Board & Committees

Five (5) Board Meetings were held during the financial year 2011- 2012 and the gap between two Board Meetings did not exceed 4 months. The Board meetings were held on 12th May, 2011, 12th August, 2011, 31st August, 2011, 14th November, 2011 and 14th February, 2012. The names of members of the Board, No of Board Meeting held during the financial year 2011-2012, their attendance at the Company's Board Meetings, Last Annual General Meeting, the number of Directorship and Chairmanship / Membership in other Companies are given below:

Name of the Director	Category	No. of Board Meeting held attended during 2011-2012		Whether attended Last AGM	No. of Directorship Companies	No. of Chairmanship / Membership in other Companies	
		Held	Attended			Chairmanship	Membership
Mr. J. P. Choksi	Chairman & Managing Director	5	5	Yes	11	Nil	9
Mr. P. J. Choksi	Executive Non Independent Director	5	5	Yes	7	Nil	6
Dr. M. G. Dhapalapur	Executive Non Independent Director	5	5	Yes	Nil	Nil	Nil
Mr. A. M. Tarale	Non Executive Independent Director	5	5	Yes	Nil	Nil	Nil
Dr. Sharat S. Gandhi	Non Executive Independent Director	5	5	Yes	Nil	Nil	Nil
Mr. Khantilal N. Sanghavi	Non Executive Independent Director	5	2	No	Nil	Nil	Nil

None of the Director is a member in more than 10 committees and is not a Chairman in more than 5 committees across all Companies in which he is a Director.

As per the requirement of Clause 49 of the Listing Agreement the Company has held one Board meeting in every quarter and the maximum time gap between any two meetings were not more than four months.

GUFIC BIOSCIENCES LIMITED

The information as required under Annexure IA to Clause 49 of the Listing Agreement is made available to the Board. The agenda and the papers for consideration at the Board meeting are circulated to the Directors in advance before the meetings. Adequate information is circulated as part of the Board papers and is also made available at the Board Meetings to enable the Board to take informed decisions. Where it is not practicable to attach Supporting / relevant document(s) to the Agenda, the same are tabled at the meeting and specific reference to this is made in the Agenda.

(D) Code of Conduct

The Board has laid down a code of conduct for all Board members and senior management of the company. The code of conduct is posted on the website of the company.

The Annual Report of the company contains a declaration signed by the CEO that all Board members and senior management personnel had affirmed compliance with the code for the year 2010-12.

II. AUDIT COMMITTEE:

(A) Qualified and Independent Audit Committee

The Audit Committee consists of Three (3) Directors, Non Executive and Independent.

The Head of Internal Audit and Representative of Statutory Auditors are invitees to the Committee meetings.

The Company Secretary acts as a Secretary to the Committee.

The present composition of the Audit committee and Meetings attended by them during the financial year ended on 31st March, 2012, is as follows:

Name of Director	Designation	Category	No of Meetings during Financial year	
			Held	Attended
Mr. Ashok Tarale	Chairman	Non-Executive Independent Director	5	5
Dr. Sharat Gandhi	Member	Non-Executive Independent Director	5	5
Mr. Khantilal N. Sanghavi	Member	Non-Executive Independent Director	5	2

Mr. Ashok Tarale, Chairman of Audit Committee attended the last Annual General Meeting held on 26th September, 2011

(B) Meetings of Audit Committee

The audit committee should meet at least four times in a year and not more than four months shall elapse between two meetings.

During the financial year under review, Five (5) meetings of the Audit Committee were held i.e. on 12th May, 2011, 12th August, 2011, 31st August, 2011, 14th November, 2011 and 14th February, 2012.

The requisite quorum was present at all audit committee meetings as per Clause 49 of the Listing Agreement.

(C) Terms of reference and powers of Audit Committee:

Terms of reference of the Audit Committee include approving and implementing the audit procedures, reviewing financial reporting systems, internal control systems and control procedures and ensuring compliance with the regulatory guidelines and also include those specified under the revised Clause 49 of the Listing Agreement as well as under Section 292A of the Companies Act, 1956.

Powers of the Audit Committee – The audit committee has powers that include the following:

- (a) to investigate any activity of the company within its terms of reference,
- (b) to seek information from any employee,
- (c) to obtain outside legal or other professional advice,
- (d) to secure attendance of outsiders with relevant expertise, if it considers necessary.

SHAREHOLDERS' & INVESTORS' GRIEVANCE COMMITTEE:

I. Composition

The Committee comprises of Two (2) Directors and Committee functions under the Chairmanship of an Independent Director. The present composition of the Shareholders' & Investors' Grievance Committee and meetings attended by them during the financial year ended on 31st March, 2012, is as follows:

Name of Director	Designation	Category	No of Meetings during Financial year	
			Held	Attended
Dr. Sharat Gandhi	Chairman	Non-Executive Independent Director	4	4
Mr. Ashok Tarale	Member	Non-Executive Independent Director	4	4

The Company Secretary acts as a Compliance Officer of the Committee

Meeting of the Shareholders' & Investors' Grievance Committee

During the year 4 [four] meetings were held on 12th May, 2011, 12th August, 2011, 14th November, 2011 and 14th February, 2012.

Powers and Role of Committee

- The Committee is empowered to collect the relevant information from all departments, which would be useful to satisfy the requirements of the shareholders.
- Give required information to shareholders and solve the problems, complaints, grievances etc. of the shareholders promptly.
- Looks into redressal of shareholders' complaints like delays in transfer of shares, non-receipt of balance sheet, non-receipt of declared dividends, etc.
- Oversees the performance of the Registrar and Transfer Agents and recommends measures for overall improvement in the quality of investor services.

Summary of Investors Complaints received and resolved to the satisfaction of the shareholders during the financial year 2011-2012

Complaints pending at beginning of the year	NIL
Complaints received during the year	19
Complaints resolved during the year	19
Complaints pending at beginning of the year	NIL

Amount Transferred to IEPF Account

As per the provision of Section 205C of the Companies Act, 1956, the Company is required to transfer the unclaimed Dividends, remaining unclaimed and unpaid for a period of seven years from the due date to the Investor Education and Protection Fund (IEPF) set up by the Central Government.

The Company has transferred unclaimed dividends, remaining unclaimed and unpaid for the financial year 2003-2004 to the Investor Education and Protection Fund (IEPF).

REMUNERATION COMMITTEE:

I. Composition

The Board of Directors of the Company has constituted a Remuneration Committee, despite it being a non mandatory requirement, which has been reconstituted from time to time.

Presently the Remuneration Committee comprises of the following qualified and independent directors.

GUFIC BIOSCIENCES LIMITED

2. Meeting of the Remuneration Committee

During the financial year 2011-2012 No Remuneration Committee Meeting was held.

Name	Designation	Category
Mr. Sharat S. Gandhi	Chairman	Non-Executive Independent Director
Mr. Ashok Tarale	Member	Non-Executive Independent Director
Mr. Khantilal N. Sanghavi	Member	Non-Executive Independent Director

3. Role of the Committee

To determine the policy on specific remuneration packages for Executive / Whole- time Directors including pension rights and any compensation payments.

Recommends to the Board the remuneration of the Executive Directors in all its forms (i.e. salary, contribution to provident fund, superannuation fund, gratuity, bonus, stock option, compensation for loss of office, other amenities, perquisites etc.).

Takes into account the financial position of the Company, profitability and trend in the industry, appointee's qualification, experience, past performance, past remuneration etc. and brings out objectivity in determining the remuneration package, while striking a balance between company's interest and that of the shareholders.

The remuneration policy is directed towards rewarding performance, based on review of achievements on a periodical basis. The remuneration policy is in consonance with the existing industry practice.

The Details of remuneration paid to Managing Director and Whole-time Directors during the financial year 2011-2012:

Sr. No	Name of Director	Salary/ Remuneration (p.a) in Rs.	Perquisites /Allowances (Rs)	Performance Linked Bonus / Commission (Rs)	Stock Options
1	Mr. Jayesh Choksi	8,40,000	3,72,000	3,21,360	Nil
2	Mr. Pranav Choksi	78,000	4,02,000	8400	Nil
3	Mr. M.G. Dhapalapur	80,400	2,58,600	6000	Nil

III. SUBSIDIARY COMPANIES

The Company neither has any Subsidiary Company nor is it a Subsidiary of any other Company.

GENERAL BODY MEETINGS:

Details of Venue, Date and Time of the Last Three Annual General Meetings are as Follows:

Year	Venue	Date	Time
2008-2009	Hotel Parle International, Vile Parle East, Mumbai – 400 057.	30th September, 2009	2.30 P.M.
2009-2010	Hotel Parle International, Vile Parle East, Mumbai – 400 057.	30th September, 2010	2.30 P.M.
2010-2011	Hotel Parle International, Vile Parle East, Mumbai – 400 057.	26th September, 2011	2.30 P.M.

MEANS OF COMMUNICATION:

The Company regularly intimates quarterly unaudited as well as yearly audited financial results to the stock exchanges, immediately after the same are taken on record by the Board. These results are published in Business Standard (English edition), Mumbai Lakshadweep (Hindi edition). These are not sent individually to the shareholders.

The Company's results, annual reports and official news releases are displayed on the company's web-site www.guficbio.com. The said company's website also containing basic information about the company includes information about the company's business, financial information, shareholding pattern, compliance with corporate

governance, company's director, registrar & transfer agent, contact information of the designated officials of the company who are responsible for assisting and handling investor grievances etc. The Company had meetings with and made presentations to the institutional investors and analysts during the year.

The Management Discussion and Analysis Report forms part of this Annual Report.

All price sensitive information and announcements are communicated immediately after the Board decisions to the Stock Exchanges, where the Company's shares are listed, for dissemination to the shareholders.

INDEPENDENT DIRECTORS:

None of the Independent Directors have any pecuniary relationship or transactions with the Company, its Promoters, its Directors, its senior management and/or associates companies as follows

CEO AND CFO CERTIFICATION:

The Chairman and Managing Director and the Chief Financial Officer of the Company have given annual certification on financial results and internal controls to the Board in terms of Clause 49 and annexed to this report.

GENERAL SHAREHOLDERS INFORMATION:

Annual General Meeting: Date, Time and Venue	24th August, 2012 At 2.30 PM At Hotel Parle International, Vile Parle East, Mumbai-400 057
Date of Book Closures	20th August, 2012 to 24th August, 2012 (Both Days Inclusive)
Financial Calendar: Results for quarter ended 30th June, 2011 Results for quarter ended 30th September, 2011 Results for quarter ended 31st December, 2011 Results for quarter ended 31st March, 2012	Second Week of August, 2011 Third Week of November, 2011 Third Week of February, 2012 Third Week of May, 2012
Dividend Payment Date	Dividend, if declared, will be paid to shareholders within 30 days from the date of Annual General Meeting
The Company is Listed at Demat ISIN	Bombay Stock Exchange Limited (Stock code: 509079) and National Stock Exchange of India Limited (Stock Code: GUFICBIO) INE742B01025 (NSDL & CDSL)
Name Address Telephone No Fax Email of Registrar & Share Transfer Agents	Link Intime (I) Private Limited C- 13, Pannalal Silk Milk Compounds, L.B.S Marg, Bhandup West, Mumbai – 400 078. Tel No: (022) 2594 6970 Fax No: (022) 2594 6969 Email: rnt.helpdesk@linkintime.co.in

Distribution of Shareholding (As on 31st March 2012)

	SHAREHOLDERS		NUMBER OF SHARES	
	NUMBER	%	NUMBER	%
UP TO 500	9591	67.6184	2294926	2.9669
501-1000	2325	16.3917	2061869	2.6656
1001-2000	1155	8.1430	1862674	2.4081
2001-3000	384	2.7073	1013145	1.3098
3001-4000	195	1.3748	710193	0.9182
4001-5000	172	1.2126	827709	1.0701
5001-10000	221	1.5581	1646319	2.1284
10001 & ABOVE	141	0.9941	66933165	86.5329
TOTAL	14184	100.0000	77350000	100.0000

GUFIC BIOSCIENCES LIMITED


Monthly Highs and Lows for the period April 2011 to March 2012

(₹ in Lacs)

Month	The Stock Exchange, Mumbai			National Stock Exchange		
	High (₹)	Low (₹)	Monthly volume	High (₹)	Low (₹)	Monthly volume
April, 2011	6.90	5.71	129327	6.75	5.60	239502
May, 2011	8.10	5.82	410830	8.15	5.90	470197
June, 2011	8.70	6.50	345361	8.60	6.55	266948
July, 2011	7.25	6.20	76945	7.20	6.20	61876
August, 2011	6.45	5.00	78195	6.45	5.00	44636
September, 2011	7.50	5.63	159011	7.65	5.85	103792
October, 2011	7.30	6.12	172304	7.30	6.10	210942
November, 2011	7.30	5.36	157249	7.25	5.40	60369
December, 2011	6.68	4.65	94129	6.70	4.70	149502
January, 2012	5.94	4.51	77848	6.35	4.65	104632
February, 2012	6.75	5.11	300565	6.40	5.10	150539
March, 2012	5.75	4.25	143795	5.50	4.55	123210


Comparison of the Company' share price with Nifty

Historic Graphs




Comparison of the Company' share price with BSE Sensex

Historic Graphs



SHAREHOLDING PATTERN AS ON 31ST MARCH, 2012:



SHAREHOLDING PATTERN OF GUFIC BIOSCIENCES LIMITED AS ON 31.03.2012

	Category of shareholder(II)	Number of shareholders (III)	Total number of shares (IV)	Number of shares held in dematerialized form (V)	%
(A)	Shareholding of Promoter and Promoter Group				
	Individuals/ Hindu Undivided Family	4	28,173,376	28,173,376	36.42
	Bodies Corporate	2	25,854,287	25,854,287	33.43
	Total Shareholding of Promoter and Promoter Group	6	54,027,663	54,027,663	69.85
(B)	Public shareholding				
	Insurance Companies	1	1,199,517	1,199,517	1.55
	Bodies Corporate	240	8,891,638	8,891,638	11.50
	Individuals				
	i. Individual shareholders holding nominal share capital up to Rs. 1 lakh.	13,613	11,811,746	11,811,746	15.50
	ii. Individual shareholders holding nominal share capital in excess of Rs. 1 lakh.	2	780,167	780,167	1.01
	Any Other (Specify)				
	1. Directors/Relative	-	-	-	-
	2. Clearing Member	37	104,977	104,977	0.14
	3. HUF	192	356,579	356,579	0.46
	4. NRIs	46	85,886	85,886	0.11
	5. NRN	23	42,809	42,809	0.06
	6. Market Makers	24	49,018	49,018	0.06
	Total Public Shareholding (B)	14,178	23,322,337	23,101,865	30.15
	TOTAL (A)+(B)	14,184	77,350,000	77,129,528	100.00

DISCLOSURES:

During the year under review besides the transactions reported in Notes to Accounts (Refer note No.27) there were no other related transactions with the promoters, directors, management and subsidiaries that have potential conflict with the interest of the Company at large. During the last three years, there were no strictures or penalties imposed by SEBI or the stock Exchange or any statutory authority for non compliance of any matter related to capital markets. The Company has complied with all mandatory requirements of the Clause 49 of the Listing Agreement. The Company has reviewed the Non Mandatory requirements under Clause 49 and these shall be adopted / complied by the Company on need basis. The Remuneration Committee, a Non-Mandatory requirement, has been constituted and the details on this have been mentioned earlier in this Report. Besides these, efforts are being made to move towards the regime of unqualified financial statement.

DECLARATION ON CODE OF CONDUCT

As provided under clause 49 of the Listing Agreement with the Stock Exchange(s), it is hereby declared that all the Board members and the Senior Management personnel of the Company have affirmed compliance with the Code of Conduct for the year ended 31st March, 2012. A declaration by CEO affirming compliance to the Code of Conduct by Board Members and Senior Management Executives is also annexed separately at the end of this report.

For and on behalf of the Board of Directors,

Place: Mumbai
Date: 10th July, 2012

Jayesh Choksi
Chairman & Managing Director

CEO/CFO CERTIFICATIONS UNDER CORPORATE GOVERNANCE REPORT

A. Declaration regarding compliance with the Code of Conduct by Board Members and Senior Management personnel

This is to certify that as per Clause 49 of the Listing Agreement:

1. The code of conduct has been laid down for all the Board Members and Senior Management and other employees of the Company.
2. The code of conduct has been posted on the website of the Company.
3. The Board members and Senior Management Personnel have affirmed compliance with the Company's code of conduct for the year 2010-11.

B. Certification of Financial Results

The Board of Directors
Gufic Biosciences Ltd.
Mumbai

(A) I have reviewed financial statements and the cash flow statement for the year and that to the best of their knowledge and belief:

- (i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
- (ii) these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

(b) There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the company's code of conduct.

(c) I accept responsibility for establishing and maintaining internal controls for financial reporting and that I have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which I am aware and the steps I have taken or propose to take to rectify these deficiencies.

(d) I have indicated to the auditors and the Audit committee

- (i) significant changes in internal control over financial reporting during the year;
- (ii) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
- (iii) instances of significant fraud of which I have become aware and the involvement therein, if any, of the management or an employee having a significant role in the company's internal control system over financial reporting.

Place: Mumbai
Date: 10th July, 2012

Jayesh Choksi
Chairman & Managing Director

AUDITORS' REPORT ON CORPORATE GOVERNANCE

To,
The Members of Gufic Biosciences Ltd.,

We have reviewed the records concerning the Company's compliance of conditions of Corporate Governance as stipulated in Clause 49 of the Listing Agreement entered into, by the Company, with the Stock Exchanges in India, for the financial year ended 31st March, 2012.

The compliance of conditions of corporate governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

We have conducted our review on the basis of the relevant records and documents maintained by the Company and furnished to us for the review, and the information and explanations given to us by the Company.

Based on such a review and to the best of our information and according to the explanations given to us, in our opinion, the Company has complied with the conditions of corporate Governance, as stipulated in Clause 49 of the said Listing Agreements.

We state that as per the records maintained, no investor grievances against the company are pending for a period exceeding one month before shareholders/investors Grievance Committee.

We further state that, such compliance is neither an assurance as to the future viability of the Company, nor as to the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Mayur Chokshi & Co.
Chartered Accountants

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
Membership No. 33936
Mumbai : 10th July, 2012

GUFIC BIOSCIENCES LIMITED

AUDITORS' REPORT

To;

The Members of Gufic Biosciences Ltd,

1. We have audited the attached Balance Sheet of "GUFIC BIOSCIENCES LTD" as at March 31, 2012, the Profit and Loss Account and also the Cash Flow Statement of the Company for the year ended on that date, annexed thereto. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
2. We conducted the audit in accordance with auditing standards generally accepted in India. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
3. As required by the Companies (Auditor's Report) Order, 2003, issued by the Central Government of India in terms of sub-section (4A) of Section 227 of the Companies Act, 1956, we enclose in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the said Order.
4. Further to our comments in the annexure referred to above, we report that:
 - a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of the books;
 - c) The Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report are in agreement with the Books of Account;
 - d) On the basis of written representation received from the Directors, as on March 31, 2012 and taken on record by the Board of Directors, we report that none of the Directors are disqualified as at March 31, 2012 from being appointed as Director in term of Clause (g) of sub-section (1) of Section 274 of the Companies Act, 1956;
 - e) Attention is invited to the fact that we have relied upon the Board's/ Management's assertions, opinion, view, representation and various other certificates produced before us, *inter-alia*, in respect of and as detailed in the note nos. 2.29, 2.30, 2.32 and 2.44.
 - f) Our observation on the said accounts are given below:
 - (i) *We are unable to express our opinion on recoverability of debts of ₹ 174.48 Lacs which are overdue for more than one year and of Loans and Advances of ₹ 37.76 Lacs which are outstanding for more than three years. In the absence of appropriate evidences, we are unable to ascertain its recoverability and its impact on the accounts of the Company. However, in the opinion of the management no provision is required in respect of such debts since they are good and recoverable in nature. (Refer Note No.2.33)*
 - (ii) *Certain transactions entered into by the Company with companies in which Directors are interested are in violation of Section 297 of the Companies Act, 1956, which requires the prior approval of the Central Government, (Refer Note 2.35)*
 - g) In our opinion, and to the best of our information and according to the explanations given to us, the Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956.

- h) In our opinion and to the best of our information and according to the explanations given to us, the said accounts with notes thereon when read in conjunction with the para (e) above, give the information required by the Companies Act, 1956, in the manner so required and **subject to para 4(f)** above, the impact whereof can not be ascertained, give a true and fair view in conformity with the accounting principles generally accepted in India:
- i] In the case of the Balance Sheet of the state of affairs of the Company as at March 31, 2012;
 - ii] In the case of the Profit and Loss Account, of the profit for the year ended on that date and
 - iii] In the case of Cash Flow Statement, of the cash flows for the year ended on that date.

For Mayur Chokshi & Co.
Chartered Accountants

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
Membership No. 33936
Mumbai : 10th July, 2012

GUFIC BIOSCIENCES LIMITED

ANNEXURE TO THE AUDITOR'S REPORT

(ANNEXURE REFERRED TO IN PARAGRAPH 3 OF OUR REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2012 OF GUFIC BIOSCIENCES LIMITED)

- i. (a) The Company is in the process of updating its records showing full particulars, including quantitative details and situation of fixed assets.
(b) As explained to us, fixed assets of the Company, have been physically verified by the Management during the year. In our opinion, period of verification is reasonable having regard to the size of the company and nature of its assets. No material discrepancies have been reported on such verification.
(c) The Company has not disposed off any substantial part of its fixed assets so as to affect its going concern.
- ii. According to the information and explanations given to us and based on the certificate issued by the internal auditor, who has conducted physical verification and valuation fixed assets, we state that ;
 - (a) the Inventory of the Company has been physically verified by the Management during the year. In our opinion frequency of verification needs to be increased.
 - (b) the procedures of physical verification of inventory followed by the Management, are reasonable and adequate in relation to the size of the Company and the nature of its business;
 - (c) the Company is maintaining proper records of its inventory and the discrepancies which were noticed on physical verification of Inventory as compared to book records, have been properly dealt with in the books of account.
- iii (a) According to the information and explanations given to us, the Company has not granted secured or unsecured loans to companies, firms or other parties covered in the register maintained u/s 301 of the Companies Act, 1956. except interest free security deposits given (Refer note 2.13)
(b) According to the information and explanations given to us, the Company has taken advances in the nature of loans from four Companies / Parties covered in the register maintained u/s 301 of the Companies Act, 1956. The maximum amount of loans taken during the year was ₹ 312.08 Lacs and the year end balance was ₹ 266.90 Lacs.
(c) The advances / loans are interest free in nature and other terms and conditions of loans taken by the company, secured or unsecured are prima facie not prejudicial to the interest of the company.
(d) There are no specific stipulations as to repayment of such advances / loans.
- iv. In our opinion and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the Company and the nature of its business, for fixed assets and sale of services. *However, internal control procedures in respect of purchase of Inventory and sale of goods need to be strengthened so as to commensurate with the size of the company.* Other than above, no major weaknesses have been noticed in the internal control systems.
- v. (a) To the best of our knowledge and belief and according to the information and explanations given to us, we are of the opinion that during the year, the particulars of contracts/arrangements that were required to be entered in the register maintained in pursuance of section 301 of the Companies Act, 1956 have been so entered.
(b) In our opinion and according to the information and explanations given to us, the transactions made in pursuance of contracts or arrangements entered in register maintained u/s 301 of the Companies Act, 1956 and exceeding the value of ₹ Five Lacs have been made at prices which are reasonable having regard to prevailing market prices at the relevant time.
- vi. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of section 58A and 58 AA or any other provisions of the Companies Act, 1956, and the rules framed thereunder during the year. To the best of our knowledge and according to information and explanations given to us, no order has been passed by the Company Law Board or any court or any other Tribunal.
- vii. *In our opinion, Company has an internal audit system which needs to be strengthened so as to commensurate with the size of the Company and nature of its business.*

- viii. According to information and explanations provided to us, the Central Government has prescribed under section 209(1)(d) of the Companies Act, 1956 the maintenance of cost records in respect of certain products manufactured by the Company viz. Formulations, Bulkdrugs. We have broadly reviewed the books of account maintained by the company and are of the opinion that *prima facie*, the prescribed accounts and records have been maintained by the company. We have not, however, made a detailed examination of records with a view to determine whether they are accurate or complete. To the best of our knowledge and according to the information given to us, the Central Government has not prescribed the maintenance of cost records under Section 209(1) (d) of the Companies Act, 1956, for any other products of the company.
- ix. (a) According to the information and explanations given to us and according to the records of the Company, *we have to state that, the company has not been regular in depositing undisputed statutory dues of Provident fund, Employees' State Insurance, Income Tax, Dividend Distribution Tax, Income tax deducted at source, Sales tax and Excise Duty.* We are informed that there are undisputed demand outstanding, as at 31st March 2012 for a period of more than six months from the date they became payable.
- (b) According to the information and explanations given to us, there are dues in respect of Income Tax, Sales tax, Service Tax, Customs Duty, Excise Duty and Cess, which have not been deposited.
- x. The Company does not have accumulated losses at the end of the financial year March 31, 2012. Without considering the effect of our observation stated in the Auditor's Report, the impact where of on the profits can not be ascertained, the Company has not incurred any cash losses during the financial year ended March 31, 2012 and in the immediately preceding financial year.
- xi. According to the information and explanations given to us and based on the documents and records produced to us, the Company has not defaulted in repayment of dues to banks.
- xii. According to the information and explanations given to us, the Company has not granted loans and advances on the basis of security by way of pledge of shares and other securities.
- xiii. In our opinion and according to the information and explanations given to us, the nature of activities of the Company does not attract any special statute applicable to chit fund and nidhi / mutual benefit fund/societies.
- xiv. The Company does not deal or trade in shares, securities, debentures and other investments.
- xv. According to the information and explanations given to us, the Company has not given any guarantee for loans taken by others from banks or financial institutions, the terms and conditions whereof are prejudicial to the interest of the Company.
- xvi. According to the information and explanations given to us, the Company has not obtained any term loan during the year.
- xvii. According to the information and explanation given to us and on the overall examination of the Balance Sheet and Cash Flow of the Company, we report that the Company has neither raised any long term nor short term funds during the year.
- xviii. The Company has not made any preferential allotment of shares to parties or companies covered in the register maintained under section 301 of the Companies Act, 1956.
- xix. The Company did not issue any debentures during the year.
- xx. The Company has not raised any money through a public issue during the year.
- xxi. Based on the audit procedures performed and information and explanations given by the management, we report that no fraud on or by the Company has been noticed or reported during the year.

For Mayur Chokshi & Co.
Chartered Accountants

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
Membership No. 33936
Mumbai : 10th July, 2012

GUFIC BIOSCIENCES LIMITED

BALANCE SHEET AS AT 31ST MARCH, 2012

	Note No.	(₹ in Lacs)	As at 31.3.2012 (₹ in Lacs)	As at 31.3.2011 (₹ in Lacs)
I. EQUITY AND LIABILITIES				
(1) SHAREHOLDERS' FUNDS				
a) Share Capital	2.1	773.50		773.50
b) Reserves and Surplus	2.2	1,177.92		1,070.16
			1,951.42	1,843.66
(2) NON-CURRENT LIABILITIES				
a) Long-term Borrowings	2.3	431.80		533.02
b) Deferred Tax Liabilities (Net)	2.4	241.50		251.88
c) Other Long Term Liabilities	2.5	101.50		109.00
d) Long-term Provisions	2.6	99.73		76.94
			874.53	970.84
(3) CURRENT LIABILITIES				
a) Short-term Borrowings	2.7	1,531.97		1,311.44
b) Trade Payables	2.8	2,221.56		1,464.42
c) Other Current Liabilities	2.9	642.28		348.45
d) Short-term Provisions	2.10	191.02		120.98
			4,586.83	3,245.29
TOTAL			7,412.78	6,059.79
II. ASSETS				
1) NON-CURRENT ASSETS				
a) Fixed Assets	2.11			
i) Tangible Assets		1,726.96		1,649.10
ii) Intangible Assets		44.09		83.00
iii) Capital Work-in-Progress		106.54		-
iv) Intangible Assets Under Development		-		-
		1,877.59		1,732.10
b) Non-current Investments	2.12	0.92		0.92
c) Deferred Tax Assets (Net)	-	-		-
d) Long-term Loans and Advances	2.13	548.86		476.58
e) Other Non-current Assets	2.14	5.18		5.93
			2,432.55	2,215.53
2) CURRENT ASSETS				
a) Current Investments	2.15	-		-
b) Inventories	2.16	1,690.94		1,276.67
c) Trade Receivables	2.17	2,257.15		1,764.07
d) Cash and Cash Equivalents	2.18	96.27		94.75
e) Short-term Loans and Advances	2.19	860.86		656.07
f) Other Current Assets	2.20	75.01		52.70
			4,980.23	3,844.26
TOTAL			7,412.78	6,059.79

Significant Accounting Policies and Notes to Accounts I & 2

Notes Referred to above form an integral part of the Financial Statements

As per our Report of even date attached

For Mayur Chokshi & Co
Chartered Accountants

For and on behalf of the Board of Directors

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
(Membership No.33936)
Mumbai - 10th July, 2012

Jayesh P. Choksi
Chairman &
Managing Director

Mumbai - 10th July, 2012

Dr. Sharat Gandhi
Director

Prakash Khulbe
Company Secretary

PROFIT AND LOSS STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2012

	Note No.	(₹ in Lacs)	Year Ended 31.3.2012 (₹ in Lacs)	Year Ended 31.3.2011 (₹ in Lacs)
INCOME				
Revenue from operations	2.21		8,356.51	7,146.53
Other Income	2.22		36.77	16.24
Total Revenue			8,393.28	7,162.77
EXPENDITURE				
Cost of Materials Consumed	2.23	2,588.85		2,234.26
Purchase of Stock-in-Trade	2.24	1,953.39		1,751.41
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	2.25	(46.22)		(291.63)
Employee Benefits Expenses	2.26	460.28		421.29
Finance Costs	2.27	263.07		190.58
Depreciation and Amortisation Expenses		188.12		180.66
Other Expenses	2.28	2,688.78		2,439.16
Total Expenses			8,096.27	6,925.73
Profit Before Extraordinary Items and Tax			297.01	237.04
Extraordinary Items			-	-
Profit Before Tax			297.01	237.04
Tax Expense				
Current Tax (Including interest of ₹ 5.95 Lacs, Prev Yr ₹ 2.40 Lacs)		125.50		60.41
Deferred Tax		(10.38)		28.54
Short / (Excess) Tax Provisions of Earlier Years		29.18		1.69
			144.30	90.64
Profit for the Year			152.71	146.40
Earnings per equity share (Refer Note 2.43)				
a) Basic			0.20	0.19
b) Diluted			0.20	0.19
Significant Accounting Policies and Notes to Accounts I & 2				

Notes Referred to above form an integral part of the Financial Statements

As per our Report of even date attached

For Mayur Chokshi & Co
Chartered Accountants

For and on behalf of the Board of Directors

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
(Membership No.33936)
Mumbai - 10th July, 2012

Jayesh P. Choksi
Chairman &
Managing Director
Mumbai - 10th July, 2012

Dr. Sharat Gandhi
Director

Prakash Khulbe
Company Secretary

GUFIC BIOSCIENCES LIMITED

CASH FLOW STATEMENT PURSUANT TO CLAUSE 32 OF LISTING AGREEMENT FOR THE PERIOD YEAR ENDED MARCH 31,2012

	Year Ended 31.03.2012 ₹ in Lacs	Year Ended 31.03.2011 ₹ in Lacs
A. Cash flow from operating Activities		
Net Profit before tax	297.01	237.04
Add : Adjustment for:		
Depreciation	188.12	180.66
Provision for Gratuity/Leave Encashment	18.64	10.57
Interest	263.07	190.58
Loss on sale of Assets / Due to Fire	0.66	3.71
Dividend / Interest Received	(1.52)	(1.02)
Bad Debts	17.65	-
Sundry Bal W/off	(0.35)	(0.41)
Operating profit before Working Capital Changes	783.28	621.13
Movement in working capital		
Increase / (decrease) in Trade Payables	757.14	99.53
Increase / (decrease) in Long-term Provisions	4.15	(8.49)
Increase / (decrease) in Short-term Provisions	(48.79)	7.99
Increase / (decrease) in Other Current Liabilities	296.77	(39.95)
Increase / (decrease) in Other Long-term Liabilities	(7.50)	8.70
Decrease / (increase) in Trade Receivables	(475.43)	(259.54)
Decrease / (increase) in Inventories	(414.27)	(241.14)
Decrease / (increase) in Long-term Loans and advances	(72.28)	(7.65)
Decrease / (increase) in Short-term Loans and advances	(204.80)	(74.39)
Decrease / (increase) in Other Current Assets	(22.31)	70.74
Decrease / (increase) in Other Non-Current Assets	0.75	(0.96)
Cash Generated from Operations	596.71	175.97
Income Tax Paid	(80.26)	(71.94)
Net Cash Generated from Operating Activity (A)	516.45	104.03
B. Cash Flow From Investing Activities		
Interest Received	1.47	0.97
Sale of Fixed Assets	-	18.50
Purchase of Fixed Assets	(334.13)	(222.66)
Dividend Received	0.05	0.05
Net Cash From Investing Activities (B)	(332.61)	(203.14)
C. Cash Flow from Finance Activities		
Increase / (Decrease) in Long-term Borrowings	(101.21)	270.31
Increase / (Decrease) in Short-term Borrowings	220.53	44.28
Dividend Paid	(38.57)	(38.15)
Interest Paid	(263.07)	(190.58)
Net Cash From Finance Activity (C)	(182.32)	85.86
Net Increase in Cash or Cash equivalent (A+B+C)	1.52	(13.25)
Cash and Cash Equivalent at Beginning of Period	94.75	108.00
Cash and Cash Equivalent at the end	96.27	94.75

As per our Report of even date attached
For Mayur Chokshi & Co
Chartered Accountants

For and on behalf of the Board of Directors

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
(Membership No.33936)
Mumbai - 10th July, 2012

Jayesh P. Choksi
Chairman &
Managing Director

Mumbai - 10th July, 2012

Dr. Sharat Gandhi
Director

Prakash Khulbe
Company Secretary

ACCOUNTING POLICIES AND NOTES FORMING PART OF THE BALANCE SHEET AND PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2012.

NOTE I SIGNIFICANT ACCOUNTING POLICIES:

(A) BASIS FOR PREPARATION OF FINANCIAL STATEMENTS:

The Financial Statements are prepared under the historical cost convention in accordance with the applicable Accounting Standards pursuant to Companies (Accounting Standards) Rules, 2006. All income and expenditure having material bearing on the financial statements are recognised on accrual basis.

The preparation of financial statements requires the Management to make certain estimates and assumptions in the reports amounts of assets and liabilities (Including contingent liabilities) as on the date of the financial statements and reported income and expenditure during the reported period. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable.

(B) FIXED ASSETS: Fixed Assets are stated at cost of acquisition or construction (net of cenvat credits). All costs relating to the acquisition and installation of fixed assets are capitalized and include borrowing costs directly attributable to construction or acquisition of fixed assets, up to the date of asset is put to use.

(C) INTANGIBLE ASSETS: Cost relating to acquisition of Brands and Technical Know-how are capitalised and amortised on a straight line basis over a period of ten years. Software cost is amortised on Straight line basis over a period of three years.

(D) INVESTMENTS: Long term investments are carried at cost less provision, if any, for permanent diminution in value of such investments. Current investments are stated at lower of cost and quoted/fair value computed category wise.

(E) INVENTORIES: Raw-materials and packing materials are valued at lower of cost or market value. Work-in process and Finished Goods are valued at cost and includes element of production overheads. Traded goods are valued at cost. Material-in-Transit valued at cost incurred to date. Consumable stores are charged to the profit and loss account in the year of its purchases.

(F) REVENUE RECOGNITION:

- (i) The Company recognises sale on despatch of goods to customers. Sales are exclusive of excise duty, sales tax and sales returns.
- (ii) Export Benefits under Duty Entitlement Pass Book Scheme, is estimated and accounted in the year of exports.
- (iii) Revenues from services are recognized when such services are rendered.

(G) EXCISE-DUTY: Excise duty is recognised on goods manufactured for sales purpose.

(H) DEPRECIATION/ AMORTISATION:

- (i) Depreciation on all the fixed assets have been charged in accordance with rates specified in Schedule XIV of Companies Act, 1956 on straight line basis.
- (ii) Capital Expenditure incurred on the assets not owned by the company are amortised over a period of five years.
- (iii) Depreciation on addition to assets or sale of assets is calculated pro-rata from the month such addition or upto the month of sale, as the case may be.

(I) RETIREMENT BENEFITS: Liability in respect of Defined Benefit Plan for Gratuity is accounted based on the Actuarial valuation, arrived at after considering the part funding through Gratuity Policy, in accordance with the method stated in the Accounting Standard 15 (Revised) on "Employees Benefits" The liability in respect of Leave Encashment has been provided as per the rules of the Company.

The contribution to Provident Fund and other recognised funds are calculated as per the prescribed rates under the relevant law and contributions are recognised in the Profit and Loss Account on an accrual basis.

(J) FOREIGN CURRENCY TRANSACTIONS: Foreign Currency transactions arising during the year are recorded at the rate of exchange prevailing on the date of transaction. Transactions which remained unsettled on Balance Sheet date are restated at the closing rate prevailing on that date. All exchange differences are dealt with in the statement of Profit & Loss Account, except those relating to the acquisition of fixed assets which are adjusted in the cost of assets.

(K) ACCOUNTING FOR TAXES: Deferred tax is recognised, for all timing differences, subject to consideration of prudence, in respect of Deferred Tax Assets.

(L) SUBSIDY ON FIXED ASSETS: Subsidy received as contribution towards cost of capital Investment project is considered as Capital Reserve.

(M) OPERATING LEASE - AS 19 LEASES : Lease charges paid for operating leases are charged to profit and loss account on a straight- line basis over the lease term.

GUFIC BIOSCIENCES LIMITED

NOTE 2 NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2012

As at
31.3.2012
(₹ in Lacs)

As at
31.3.2011
(₹ in Lacs)

2.1 SHARE CAPITAL

AUTHORISED:

10,00,00,000 Equity Shares of ₹1 Each

1,000.00	1,000.00
1,000.00	1,000.00

ISSUED, SUBSCRIBED AND FULLY PAID UP:

7,73,50,000 Equity Shares of ₹1 Each, Fully Paid Up.

773.50	773.50
773.50	773.50

Each holder of equity shares is entitled to one vote per share with a right to receive per share dividend declared by the Company. In the event of liquidation, the equity shareholders are entitled to receive remaining assets of the Company (after distribution of all preferential amounts) in the proportion of equity shares held by the shareholders. During the year, the Company has recorded Dividend @ 5% (previous year: 5%) on a share of ₹1 each.

Details of shareholders holding more than 5% shares of the Company
Equity shares of ₹1 each fully paid up held by

Name of Shareholders	As at 31st March, 2012		As at 31st March, 2011	
	No of Shares	%	No of Shares	%
a) Zircon Finance and Leasing Pvt. Ltd.	20,523,330	26.53%	20,523,330	26.53%
b) Jayesh Pannalal Choksi	18,010,259	23.28%	18,010,259	23.28%
c) Sambhav Properties Pvt Limited	7,741,550	10.01%	7,669,904	9.92%
d) Pranav Jayesh Choksi	6,875,844	8.89%	6,875,844	8.89%
e) Gufic Private Limited	5,330,957	6.89%	5,330,957	6.89%

2.2 RESERVE AND SURPLUS:

a) General Reserve :	A	134.71	134.71
b) Capital Reserve	B	12.50	12.50
c) Surplus in the Statement of Profit and Loss			
Balance at the beginning of the Year		922.95	821.65
Add : Profit for the Year		152.71	146.40
Less : Appropriations			
(a) Proposed Dividend		38.68	38.68
(b) Dividend Tax		6.27	6.42
Balance at the end of the Year	C	1,030.71	922.95
TOTAL (A+B+C)		1,177.92	1,070.16

2.3 LONG-TERM BORROWINGS

Term Loan From Bank (Secured)	119.21	165.31
Vehicle Loans (Secured)	45.69	60.15
From Directors (Unsecured)	200.00	290.00
From Related Parties (Unsecured)	66.90	17.56
	431.80	533.02

From a Bank:

Term Loans:

Secured by hypothecation and / or Equitable Mortgage of assets purchased under the term loans, other specific assets, together with hypothecation of Plant and Machinery and other movable assets situated at Navsari Unit and are further secured by Registered Mortgage of land, Corporate Guarantee and Cash collateral in the form of TDRs of ₹ 500 Lacs, all of an associate company and guaranteed by the Managing Director of Company.

The loans are repayable in 60 monthly installments of ₹ 5 lacs starting from April 2010 and ending on March 2015. The rate of interest is 3.00% above SBAR, payable at monthly rest.

Vehicle Loans:

Secured by charge on specific vehicles purchased.

These loans are repayable in 36 to 60 EMI of ₹ 19.73 Lacs (Incl Interest) starting from the date of the respective contract. The effective rate of interest ranges from 8.90 % to 13.50 %.

Unsecured Loans:

Of the above unsecured loans,

As a part of condition laid down by the Bank, ₹ 327 Lacs is to be converted into equity by 31.03.2013.

	As at 31.3.2012 (₹ in Lacs)	Current Year (₹ in Lacs)	As at 31.3.2011 (₹ in Lacs)
2.4 DEFERRED TAX LIABILITIES (NET)			
Deferred Tax Liabilities:			
Difference Between book and income tax depreciation	274.10	(2.12)	276.22
Total (A)	274.10	(2.12)	276.22
Deferred Tax Assets:			
Expenses Disallows			
a) Gratuity	41.34	6.36	34.98
b) Leave Encashment	18.11	1.90	16.21
c) Other Disallowances	(26.85)	-	(26.85)
Total (B)	32.60	8.26	24.34
Deferred Tax Liability (Net)	Total (A - B)	(10.38)	251.88

	As at 31.3.2012 (₹ in Lacs)	As at 31.3.2011 (₹ in Lacs)
2.5 OTHER LONG TERM LIABILITIES		
Security and Trade Deposits from Agents and Stockists (Refer Note 2.32)	101.50	109.00
	101.50	109.00
2.6 LONG-TERM PROVISION		
Provision for employee benefits		
i) Provision for Gratuity	60.61	39.61
ii) Leave Encashment	39.12	37.33
	99.73	76.94
2.7 SHORT-TERM BORROWINGS		
Loans repayable on Demand (Secured)		
Cash Credit Facilities From a Bank	1,531.97	1,311.44
	1,531.97	1,311.44

Secured by hypothecation of stocks and books debts and collateral security of hypothecation of all movable assets of the Company, further secured by Registered Mortgage of land, Corporate Guarantee and Cash collateral in the form of TDR (of ₹ 500 Lacs) all of the associate Company and guaranteed by the Managing Director of Company. They carry interest @ 6.75% above Base Rate of the Bank.

2.8 TRADE PAYABLES (Refer Note 2.32)	2,221.56	1,464.42
---	-----------------	-----------------

Sundry Creditors - Dues to Micro and Small Enterprises

In terms of the notification issued by the Department of Company affairs, the Company is required to make certain disclosure under the head "Sundry Creditors" in respect of dues to Micro Enterprises and Small Enterprises as defined under the "The Micro, Small and Medium Enterprises Development Act, 2006" (MSMED ACT). The Company has not yet started process of inviting information from its vendors regarding their status under MSMED Act. The Company has also not received any memorandum by such suppliers (as required to be filed with the notified authority under the MSMED Act, 2006) claiming their status as micro or small or medium enterprises. Therefore, bifurcation between Total Outstanding Dues of Micro Enterprises and Small Enterprises and other dues are not disclosed under the head "Sundry Creditors" under the head Current Liabilities and Provision.

GUFIC BIOSCIENCES LIMITED

As at
31.3.2012
(₹ in Lacs)

As at
31.3.2011
(₹ in Lacs)

2.9 OTHER CURRENT LIABILITIES

a) Current Maturities of Long-Term Debt	78.25	73.90
b) Interest accrued and due on Borrowings	22.31	26.91
c) Unpaid Dividends	5.18	5.08
d) Other Payables		
Advances from Customer (Refer Note 2.32)	280.46	18.50
Unpaid Dividend Distribution Tax	19.42	13.00
Sales Tax Payable	69.36	31.54
TDS Payable	73.40	53.23
Professional Tax Payable	0.40	1.52
ESIC, PF and Other Funds Payable	37.31	33.70
Payable to Directors	27.76	19.58
Others	28.43	71.49
	642.28	348.45

2.10 SHORT-TERM PROVISIONS

a) Provision for Employee Benefits	17.93	22.08
b) Proposed Dividend to Equity Shareholders @ ₹ 0.05 Per Share	38.68	38.68
c) Tax on Proposed Dividend (Current Year)	6.27	6.42
d) Provision for Income Tax (Net of Advance Tax of ₹ 118.76; Prev Yr ₹ 295.98)	128.14	53.80
	191.02	120.98

2.11 FIXED AND INTANGIBLE ASSETS

(₹ in Lacs)

PARTICULARS	Rate	GROSS BLOCK				DEPRECIATION				NET BLOCK	
		As at 01.04.2011 (₹)	Additions During theYear (₹)	Deduction/ Depletion During Year (₹)	As at 31.03.2012 (₹)	As at 01.04.2011 (₹)	For the Year (₹)	Deduction for the year (₹)	Total Accum. Deprn. (₹)	As at 31.03.2012 (₹)	As at 31.03.2011 (₹)
TANGIBLE ASSETS											
Plant and Machinery	4.75%	1658.71	150.33	–	1809.04	501.20	81.21	–	582.41	1226.63	1157.51
Airconditioners	4.75%	149.81	3.19	–	153.00	38.25	7.22	–	45.47	107.53	111.56
Office Equipments	4.75%	216.34	0.00	–	216.34	81.16	10.28	–	91.44	124.91	135.18
Computers	16.21%	74.13	4.67	–	78.80	65.45	2.05	–	67.50	11.31	8.68
Electrical Installation	4.75%	72.32	6.54	–	78.86	13.14	3.47	–	16.61	62.25	59.18
Vehicles	9.50%	162.00	25.61	8.71	178.91	49.82	11.67	8.20	53.29	125.61	112.18
Furniture and Fixture	6.33%	47.03	6.51	–	53.54	12.11	3.24	–	15.35	38.18	34.91
Capital Exp on Factory Bldg not owned by co. (x)	20.00%	146.68	30.74	–	177.42	116.79	30.08	–	146.87	30.54	29.90
TOTAL - (A)		2527.02	227.59	8.71	2745.91	877.92	149.22	8.20	1018.94	1726.96	1649.10
PREVIOUS YEAR (B)		2102.88	447.32	23.17	2527.02	737.55	141.33	0.96	877.92	1649.10	1366.34
INTANGIBLE ASSETS											
Computer Software (XX)	33.33%	26.28	–	–	26.28	26.16	0.12	–	26.28	–	0.12
Brand (XXX)	10.00%	249.25	–	–	249.25	199.40	24.93	–	224.33	24.93	49.86
Technical Know How (XXX)	10.00%	138.56	–	–	138.56	105.54	13.85	–	119.39	19.16	33.02
TOTAL - (C)		414.09	–	–	414.09	331.10	38.90	–	370.00	44.09	83.00
PREVIOUS YEAR (D)		414.09	–	–	414.09	291.78	39.32	–	331.10	83.00	122.31
TOTAL (A) + (C)		2941.11	227.59	8.71	3160.00	1209.02	188.12	8.20	1388.94	1771.05	1732.10
PREVIOUS YEAR (B) + (D)		2516.97	447.32	23.17	2941.11	1029.33	180.65	0.96	1209.02	1732.10	1488.65

(X) Capital Expenditure on factory building not owned by the Company is amortised over a period of 5 years.

(XX) Computer Software is amortised on straight line basis over a period of 3 years.

(XXX) Brand and R&D Knowhow are amortised on a straight line basis over a period of 10 years.

	As at 31.3.2012 (₹ in Lacs)	As at 31.3.2011 (₹ in Lacs)
--	-----------------------------------	-----------------------------------

2.12 NON-CURRENT INVESTMENTS

(At cost except otherwise stated)

Non Current Investment (NON-TRADE)

a) Quoted :

Aggregate Value of Quoted Investments

	-	-
--	---	---

b) Unquoted :

Investment in Government Securities

National Savings Certificate (At cost)

	0.42	0.42
--	------	------

Investment in Shares:

Saraswat Co-op Bank Ltd (At cost)

	0.50	0.50
--	------	------

4990 Equity Shares of Rs 10 each, fully paid up

Aggregate Value of Unquoted Investments

	0.92	0.92
--	------	------

Total (A+B)	0.92	0.92
--------------------	-------------	-------------

2.13 LONG-TERM LOANS AND ADVANCES

(Unsecured Considered good) (Refer Note 2.32)

a) Capital Advances (Refer Note 2.33)

	103.75	31.47
--	--------	-------

b) Deposits

	25.11	25.11
--	-------	-------

c) Loans and Advances to Related Parties

To Gufic Private Limited

	300.00	300.00
--	--------	--------

To Gufic Chem Private Limited

	120.00	120.00
--	--------	--------

	548.86	476.58
--	---------------	---------------

Loans and Advances to Related Parties are due from companies in which Directors are interested. The Company has given interest free security deposits to the following companies:

Gufic Private Limited.

	300.00	300.00
--	--------	--------

Maximum amount outstanding

	300.00	300.00
--	--------	--------

Gufic Chem Pvt. Ltd.

	120.00	120.00
--	--------	--------

Maximum amount outstanding

	120.00	120.00
--	--------	--------

Total Deposits

	420.00	420.00
--	---------------	---------------

Security Deposits were given to Gufic Private Ltd for use of its factory premises at Navsari for the company's manufacturing activities under an operating lease for a period of 10 years. Gufic Private Ltd. has created an Equitable Mortgage on the said factory premises in favour of the Bank for availing the credit facilities to the company. Hence, the said deposits are secured and considered good. The company has also paid lease rentals of ₹1.20 Lacs during the year for use of the factory premises.

Security deposits to Gufic Chem Private Ltd was given for supply of products and usage of its facilities at concessional rate to the Company. Such deposits are unsecured and considered good.

2.14 OTHER NON-CURRENT ASSETS

Others

	5.18	5.93
--	------	------

	5.18	5.93
--	-------------	-------------

2.15 CURRENT INVESTMENTS

	-	-
--	---	---

GUFIC BIOSCIENCES LIMITED

	As at 31.3.2012 (₹ in Lacs)	As at 31.3.2011 (₹ in Lacs)
2.16 INVENTORIES		
(As verified, valued and certified by the Management) (Refer Note 2.29, 2.30, 2.34)		
a) Raw Materials, at lower of cost or net realisable value	666.80	444.41
b) Work-in-Process, at cost	166.28	97.40
c) Finished Goods, at Lower of cost or market value	411.88	436.05
d) Packing Materials, at lower of cost or net realisable value	344.78	199.12
e) Stock-in-Trade, at Lower of cost or market value	101.20	99.69
	1,690.94	1,276.67
2.17 TRADE RECEIVABLES		
(Unsecured, Considered Good) (Refer Note 2.32, 2.33)		
Due for more than six months	277.72	192.63
Other Debts	1,979.43	1,571.44
	2,257.15	1,764.07
2.18 CASH AND CASH EQUIVALENTS		
a) Balances with banks		
In Current Accounts	37.53	71.29
Earmarked Balances with Banks:		
In Unclaimed Dividend Accounts	5.31	5.21
In Fixed Deposit (Pledged against LCs and guarantees)	34.53	17.45
	(A) 77.37	93.95
b) Cash on Hand	18.90	0.80
	(B) 18.90	0.80
Total (A+B)	96.27	94.75
2.19 SHORT-TERM LOANS AND ADVANCES		
(Unsecured, Considered Good)		
a) Loans and Advances to Related Parties		
To Gufic Private Limited	472.20	285.00
To Gufic Chem Private Limited	2.32	22.36
To Gufic Health Care Limited	0.62	-
To Gufic Stridden Bio Pharma Private Limited	1.60	6.71
To Jal Private Limited	-	11.46
b) Others (Refer Note 2.32, 2.33)		
Advance to Suppliers	364.38	310.97
Others	19.74	19.57
	860.86	656.07
Loans and Advances to Related Parties are due from companies in which Directors are interested:		
Gufic Chem Pvt. Ltd.	2.32	22.36
Maximum amount outstanding	39.56	65.39
Gufic Pvt Ltd	472.20	285.00
Maximum amount outstanding	569.98	285.00
Gufic Healthcare Ltd	0.62	-
Maximum amount outstanding	0.62	-
Gufic Stridden Biopharma Pvt. Ltd.	1.60	6.71
Maximum amount outstanding	13.29	9.82
Jal Pvt. Ltd.	-	11.46
Maximum amount outstanding	13.76	16.83
2.20 OTHER CURRENT ASSETS		
a) Balance with Central Excise	42.10	26.45
b) Export Benefit Receivable	29.43	23.46
c) Others	3.48	2.79
	75.01	52.70

Notes to the financial statements for the year ended 31 March 2012

	Year Ended 31.3.2012 (₹ in Lacs)	Year Ended 31.3.2011 (₹ in Lacs)
2.21 REVENUE FROM OPERATIONS		
a) Sale of Products (Net of Returns and Sales Tax)	8,186.42	6,936.60
b) Processing Charges (TDS ₹ 9.26; Prev Yr ₹ 8.60)	434.72	432.26
c) Other Operating Revenues	15.35	15.59
Less: Excise Duty Collected	279.98	237.92
	8,356.51	7,146.53
TURNOVER		
Formulation (manufacturing)		
Tablets	1,279.27	1,190.69
Capsules	122.46	60.17
Ointments	213.19	168.80
Syrups/Suspension	131.74	127.36
Injection	2,551.52	1,505.08
Powder	18.25	17.38
Lotion	279.09	437.70
Formulation (Trading)		
Tablets	262.74	284.81
Capsules	89.42	95.26
Syrups/Suspension	89.33	85.43
Injections	197.82	247.13
Powder	4.66	6.07
Ointments	0.90	8.07
Sanitary Napkins	227.40	406.94
Lotion	-	0.82
Castor Oil	1,085.90	771.10
Others	373.18	217.43
Bulk Drugs (Manufacturing)		
Chemicals	1,144.38	1,306.36
Sanitary Napkins (Manufacturing)		
	115.17	-
	8,186.42	6,936.60
2.22 OTHER INCOME:		
a) Interest Income (TDS ₹ 0.14; Prev Yr ₹ 0.09)	1.47	0.97
b) Dividend Received (Gross)	0.05	0.05
c) Other Non-operating Income		
i) Scrap Sales	16.73	14.31
ii) Sundry Balances Written Back (Net)	0.35	0.41
iii) Miscellaneous Income	0.07	0.21
iv) Insurance Claim received	7.84	0.29
v) Exchange Difference (Net)	10.26	-
	36.77	16.24

GUFIC BIOSCIENCES LIMITED

Year Ended
31.3.2012
(₹ in Lacs)

Year Ended
31.3.2011
(₹ in Lacs)

2.23 COST OF MATERIALS CONSUMED

(A). Consumption of Raw Material

Opening stock	444.41	542.20
Add: Purchases	2,402.21	1,722.85
Less: Closing stock	666.80	444.41

(A) 2,179.82 1,820.64

(B). Consumption of Packing Material

Opening stock	199.12	151.82
Add: Purchases	554.69	460.92
Less: Closing Stock	344.78	199.12

(B) 409.03 413.62

TOTAL (A+B) 2,588.85 2,234.26

CONSUMPTION OF RAW MATERIALS

Chemicals	1,236.66	815.50
Sugar	12.97	11.67
Herbals	119.24	95.83
Chemicals (Bulk Drugs)	773.42	769.28
Others	37.53	128.36
	<u>2,179.82</u>	<u>1,820.64</u>

Value of Imported and Indigenous Materials Consumed

	This Year		Previous Year	
	%	Value ₹ in Lacs	%	Value ₹ in Lacs
Imported	8.09	209.35	4.55	101.68
Indigenous	91.91	2,379.50	95.45	2,132.58
	100.00	2,588.85	100.00	2,234.26

Year Ended
31.3.2012
(₹ in Lacs)

Year Ended
31.3.2011
(₹ in Lacs)

2.24 PURCHASE OF STOCK-IN-TRADE

1,953.39 1,751.41

PURCHASE OF STOCK-IN-TRADE

Tablets	127.08	147.17
Capsules	46.68	46.63
Syrups/Suspension	56.73	50.47
Injection	178.78	174.94
Lotion	-	0.81
Powder	2.51	3.04
Ointments	0.87	1.84
Castor Oil	1,080.60	767.33
Sanitary Napkins	141.57	332.57
Others	318.57	226.61
	<u>1,953.39</u>	<u>1,751.41</u>

Year Ended 31.3.2012 (₹ in Lacs)	Year Ended 31.3.2011 (₹ in Lacs)
--	--

2.25 CHANGES IN INVENTORIES OF FINISHED GOODS WORK-IN-PROGRESS AND STOCK-IN-TRADE

Opening stock :

Finished Goods	436.05	209.48
Work-In-Process	97.40	75.75
Stock-In-Trade	99.69	56.28
	633.14	341.51

Closing Stock :

Finished Goods	411.88	436.05
Work-In-Process	166.28	97.40
Stock-In-Trade	101.20	99.69
	679.36	633.14

(INCREASED) / DECREASED IN STOCK

(46.22)	(291.63)
----------------	-----------------

OPENING STOCK OF WORK-IN-PROCESS

Formulation	74.99	38.01
Bulk Drugs	22.41	37.74
	97.40	75.75

CLOSING STOCK OF WORK-IN-PROCESS

Formulation	144.19	74.99
Bulk Drugs	22.09	22.41
	166.28	97.40

2.26 EMPLOYEE BENEFITS EXPENSES

a) Salaries and Wages	385.58	347.01
b) Bonus	12.76	12.11
c) Contribution to Provident and Other Funds	26.86	25.45
d) Directors' Remuneration	23.67	25.61
e) Staff Welfare Expenses	11.41	11.11
	460.28	421.29

2.27 FINANCE COSTS

a) Interest on Term Loan	41.73	33.98
b) Interest on OD Facility	161.23	137.81
c) Interest to Others	9.97	9.39
d) Other Borrowing Costs	8.98	9.16
e) Net loss on Foreign Currency Transaction and Translation	41.16	0.24
	263.07	190.58

GUFIC BIOSCIENCES LIMITED

	Year Ended 31.3.2012 (₹ in Lacs)	Year Ended 31.3.2011 (₹ in Lacs)
2.28 OTHER EXPENSES		
Consumable Stores	21.87	28.06
Power and Fuel	249.86	213.18
Labour Charges	182.04	147.63
Factory Expenses	1.12	4.06
Rent	1.64	1.20
Rates and Taxes	0.17	14.10
Repairs to Building	7.02	22.17
Repairs to Machinery	49.39	33.41
Repairs to others	15.78	15.37
Sales Tax Expenses	37.96	10.29
Printing and Stationery	20.03	19.18
Postage Telephone and Fax Exps	33.82	28.68
Office Rent	75.66	51.51
Director Sitting Fees	0.30	0.30
Insurance Charges	22.02	14.28
Travelling, Conveyance and Vehicle Exps	101.70	88.55
Legal & Professional Fees	139.26	116.06
Sundry Expenses	73.61	42.57
Foreign Currency Exchange Difference (Net)	-	22.83
Bank Charges	22.29	21.60
Testing and Laboratory Expenses	62.91	56.30
<u>Auditors Remuneration</u>		
For Statutory Audit Fees	3.37	3.31
For Tax Audit Fees	0.56	0.55
For Cost Audit Fees	0.67	-
Transport and Forwarding	148.72	180.20
Commission and Brokerage	121.59	119.74
Marketing Expenses	835.12	741.03
Sales Promotion Expenses	171.59	145.34
Advertisement	71.54	107.19
Discount	198.86	186.76
Loss on sale of Asset (Net)	0.66	3.71
Bad Debts	17.65	-
	2,688.78	2,439.16

2.29 During the earlier year, the Company introduced different modules of an ERP System integrating few of its operations at different points of time. Consequently, the Company discontinued its legacy system. Subsequently, it was found that various accounts / data could not be reconciled and as a result, the Company decided to defer further implementation until the deficiencies are resolved. Consequently, the Company reverted to legacy financial accounting systems to record transactions of the earlier as well as of the current year and draw up its books of accounts and is continuing on its dual accounting system.

As a result, some data, particularly quantitative information, has been compiled based on limited information available including from the new ERP Modules, which itself has not been tested for its accuracy. Management represents and confirms that it has taken enough care/diligence to ensure that the presented data / accounts, so computed, are materially correct and that the books of accounts shall be duly reconciled and necessary entries arising therefrom, which in the opinion of the Board will not be material, shall be given effect to in the subsequent year.

2.30 The Company has appointed internal auditor, an independent Chartered Accountant to carry out the audit of stock records maintained by the Company. The Audit inter-alia includes physical verification and valuation of inventory, summary of quantitative data with its value lying at all its factories and branches including inventory lying with the third parties and has issued a certificate dt. 20th May, 2012 valuing the inventory at ₹. 1690.94 Lacs as at 31.03.2012 and accordingly the same has been incorporated in accounts.

- 2.31** In compliance with Accounting Standard-2 (AS-2) revised, Excise Duty liability estimated at ₹ 9.72 Lacs (Previous year ₹ 8.09 Lacs) on Finished goods lying in factory premises has been loaded on the valuation of Finished goods. However, it has no impact on the Profit and Loss Account.
- 2.32** Confirmations have not been obtained with respect to balances of Other Long Term Liabilities, Trade Payables, Advances from Customers, Long Term Loans and Advances, Trade Receivables, Others Short Term Loans and Advances. These balances are subject to confirmations from the respective parties and consequential reconciliations and adjustments arising there from, if any. The management, however, does not expect any material variation.
- 2.33** Capital Advances of ₹ 8.53 Lacs (Prev Year ₹ 8.40 Lacs), Advances to Suppliers ₹ 25.06 Lacs (Prev Year ₹ 29.09 Lacs) and Advances to others ₹ 4.17 Lacs (Prev Year ₹ 3.50 Lacs) are old receivable due for more than three years and Trade Receivables of ₹ 174.48 Lacs (Prev Year ₹ 104.69 Lacs) due for more than one year which in the opinion of auditors may not be recoverable and not been provided for. The Management is of the opinion that these are good and realisable and thus no provision is required.
- 2.34** In the opinion of the management inventories of ₹ 1690.94 Lacs (Previous year ₹ 1276.67 Lacs) shown in Balance Sheet are good and do not include any slow moving, or dead stock. Due provision is made for the near expiry material and depletion in its value, if any. In the opinion of the management, all the current assets including inventories, loans and advances have a value on a realisation in the ordinary course of business at least equal to the amount at which they are stated in the Balance Sheet.
- 2.35** The Company has entered into various transactions on an Arm's-Length basis in the ordinary course of business with Companies in which Directors are interested which requires the prior approval of the Central Government u/s 297 of the Companies Act, 1956. The Company has yet to apply for compounding of offence of inadvertent non-compliance with the provisions of Sec 297 of the Act in respect of the past transactions and regularising the future transactions.

2.36 CONTINGENT LIABILITIES:

	As At 31.3.2012 (₹ in Lacs)	As At 31.3.2011 (₹ in Lacs)
A Estimated amount of contract remaining to be executed On capital account and not provided for	292.22	42.51
B Letter of Credit	239.13	10.15
C Bank Guarantee	17.00	17.49
D Claims against company not acknowledged as Debts, Being disputed	108.86	108.86
E Labor Cases	0.70	34.11
F Other Commitments		

Details of other commitments arising out of major Contracts entered into by the Company

The Company has entered into contract during December 2007 to avail Marketing Services with erstwhile Placer Mercantile and Investments Private Limited, now amalgamated with Gufic Private Limited, a company in which Managing Director and other Director are Directors and are member of the said amalgamated company. As per the Terms of Contract, the present Minimum Fees is ₹ 650 Lacs per year Plus 10% of the increase in sales turnover of products over the 2009-10, The Company is required to pay an interest free deposit, equivalent to three months of monetary expenses, to be settled on a yearly basis.

2.37 EXPENDITURE IN FOREIGN CURRENCY:

	As At 31.3.2012 (₹ in Lacs)	As At 31.3.2011 (₹ in Lacs)
A Value of Imports on C.I.F Basis: Raw Materials / Merchant Goods	293.09	329.13
B Expenditure in Foreign Currency: Traveling Expenses	17.70	23.57
Commission and Other Expenses	41.99	21.19

2.38 EARNINGS IN FOREIGN CURRENCY:

Export Sales calculated on FOB basis	871.38	1,141.67
--------------------------------------	--------	----------

GUFIC BIOSCIENCES LIMITED

2.39 Gratuity benefit plans:

The Company's Provision for Gratuity as at the close of the year has been computed by the Actuary appointed for the purpose as per the AS 15(Revised), adopting the "Projected Unit Credit Method". The Company has also taken the Policy to partly fund the liability.

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The following tables summarise the components of net benefit expense recognised in the profit and loss account and amounts recognised in the balance sheet.

	Apr 11-Mar 12	Apr 10-Mar 11
I Assumptions:		
Discount Rate	8.75%	8.25%
Rate of Return on Plan Assets	8.75%	8.25%
Salary Escalation	3.00%	3.00%
Attrition Rate	1.00%	1.00%
II Table Showing Change in Benefit Obligation:		
Liability at the beginning of the Period	9,356,950	8,392,693
Interest Cost	771,948	671,415
Current Service Cost	498,857	473,536
Past Service Cost (Vested Benefit)	-	-
Benefit Paid	(1,097,972)	(494,150)
Actuarial (gain)/loss on obligations	(68,511)	313,455
Liability at the end of the Period	9,461,272	9,356,950
III Tables of Fair value of Plan Assets:		
Fair Value of Plan Assets at the beginning of the Period	2,688,952	2,775,501
Expected Return on Plan Assets	221,839	222,040
Contributions	208,721	165,539
Benefit Paid	(1,097,972)	(494,150)
Actuarial gain/(loss) on Plan Assets	(35,356)	20,022
Fair Value of Plan Assets at the end of the Period	1,986,184	2,688,952
Total Actuarial Gain/(Loss) to be Recognised	(33,155)	(293,433)
IV Actual Return on Plan Assets:		
Expected Return on Plan Assets	221,839	222,040
Actuarial gain/(loss) on Plan Assets	(35,356)	20,022
Actual Return on Plan Assets	186,483	242,062
V Amount Recognised in the Balance Sheet:		
Liability at the end of the Period	(9,461,272)	(9,356,950)
Fair Value of Plan Assets at the end of the Period	1,986,184	2,688,952
Difference	(7,475,088)	(6,667,998)
Amount Recognised in Balance Sheet	(7,475,088)	(6,667,998)
VI Expenses Recognised in the Income Statement:		
Current Service Cost	4,98,857	473,536
Interest Cost	771,948	671,415
Expected Return on Plan Assets	(221,839)	(222,040)
Past Service Cost (Vested Benefit)	--	--
Recognised Net Actuarial (Gain)/Loss	(33,155)	293,433
To Be Recognised Expense Recognised in P&L A/C	1,015,811	1,216,344
VII Amount Recognised:		
Opening net liability	6,667,998	5,617,192
Expense as above	1,015,811	1,216,344
Employers Contribution paid	(208,721)	(165,539)
Closing net Liability	7,475,088	6,667,998
VIII Other Details:		
No of Members	173	193
Salary per month	1,413,757	1,419,516
Contribution for next year	1,258,759	681,368
IX Category of Assets:		
Insurer Managed Funds	1,986,184	2,688,952
Total	1,986,184	2,688,952

X Experience Adjustment:

Experience adjustments on plan liabilities	234,289	475,219
Experience adjustments on plan liabilities (Gain)/Loss	(35,356)	20,022

2.40 Borrowing Cost capitalised as Fixed Assets in F.Y. 2011-2012 NIL (Prev Year ₹ 11.28 Lacs)

2.41 INFORMATION ABOUT PRIMARY BUSINESS SEGMENTS

(₹ in Lacs)

Sr. No.	Particulars	Formulations		Bulk Drugs		Consumer		Total	
		31.3.2012	31.3.2011	31.3.2012	31.3.2011	31.3.2012	31.3.2011	31.3.2012	31.3.2011
1	SEGMENT REVENUE								
	Sales and Services (Inclusive of Excise and Net of returns)	6,807.51	5,070.17	1,139.81	1,306.36	673.82	992.34	8,621.14	7,368.86
	Add: Unallocated Income							52.12	31.83
	TOTAL SEGMENT REVENUE	6,807.51	5,070.17	1,139.81	1,306.36	673.82	992.34	8,673.26	7,400.69
2	SEGMENT RESULTS	1,293.43	983.61	193.77	224.69	129.78	185.57	1,616.97	1,393.87
	Less: Unallocated Expenses							868.78	785.59
	Financial Charges							263.07	190.58
	Depreciation							188.12	180.66
	Tax Provision							144.30	90.64
	PROFIT AFTER TAX							152.71	146.40
3	OTHER INFORMATION								
	Segment Assets	4,688.15	3,851.29	722.35	517.35	330.23	378.96	5,740.73	4,747.60
	Add: Unallocated Assets							1,672.04	1,312.19
	Total Assets							7,412.78	6,059.79
	Segment Liabilities	1,114.30	569.54	827.08	586.37	163.24	61.55	2,104.62	1,217.46
	Add: Unallocated Liabilities							3,356.74	2,998.67
	Total Liabilities							5,461.37	4,216.13
	Capital Expenditure								
	Capital Expenditure Incurred	185.46	421.01	42.13	26.31	--	--	227.59	447.32
	Unallocated Capital Expenditure							--	--
	Depreciation	138.17	131.48	11.05	9.86	--	--	149.22	141.33
	Unallocated Depreciation							38.90	39.32

(₹ in Lacs)

4 ADDITIONAL INFORMATION	In India		Out of India		Total	
	31.3.2012	31.3.2011	31.3.2012	31.3.2011	31.3.2012	31.3.2011
1. Revenue by Location of Customer	7,749.76	6,227.19	871.38	1,141.67	8,621.14	7,368.86
2. Segment Assets by Location of the Customer	7,412.78	6,059.79	--	--	7,412.78	6,059.79
3. Capital Expenditure by Location of the Customer	227.59	447.32	--	--	227.59	447.32

2.42 The amount of lease payments in respect of operating leases recognised in the profit and loss account was ₹ 77.18 Lacs (Previous year ₹ 68.10 Lacs) The minimum future payments during non-cancellable periods under the foregoing arrangements in the aggregate for each of the following periods is as follows :

- Not later than one year ₹ 1.20 Lacs (Previous year ₹ 1.20 Lacs)
- Later than one year but not later than five years ₹ Nil
- Later than five years ₹ Nil

During the current year ended March 31, 2012 the lease payments recognised in the Profit and Loss Account for the aforesaid arrangements amounts to ₹ 77.18 Lacs (Previous year ₹ 68.10 Lacs)

GUFIC BIOSCIENCES LIMITED

2.43 EARNINGS PER SHARE (EPS):

	Year Ended 31.3.2012 (₹ in Lacs)	Year Ended 31.3.2011 (₹ in Lacs)
Profit After Taxes	152.71	146.40
No. of Equity Share (Lacs)	773.50	773.50
Earning Per Share	0.20	0.19

2.44 Considering the nature, existing and projected sales and profitability, the Board is of the opinion that no impairment of assets is required. Being too technical, Auditors have relied upon the same and hence impairment, If any, has not been recognised

2.45 RELATED PARTY DISCLOSURES FOR THE PERIOD ENDED 31.03.2012

(₹ in Lacs)

Name of the Party Nature of Relationship	Gufic Chem Pvt Ltd	Gufic Pvt Ltd	Jal Pvt Ltd	Gufic Stridden Pvt. Ltd.	Gufic Healthcar Ltd	Zircon Finance & Leasing Pvt Ltd	Jayesh P. Choksi (Managing Director)	Pranav J. Choksi (Executive Director)	Dr. M. G. Dhaplapur Managing Director	Vipula J. Choksi (Relatives of Managing Director)
	(Controlled Through Key Managerial Personnel)									
Nature of Transaction	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)	This year (Previous year)
Purchase of Goods and exp. re-imbursement	24.33	216.34	--	--	--	--	--	--	--	--
(Previous Year)	(60.99)	(332.15)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Usage of Services	46.22	853.39	13.52	--	--	--	--	--	--	--
(Previous Year)	(46.84)	(761.05)	(13.08)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Sales of Goods	7.64	119.10	--	2.71	--	--	--	--	--	--
(Previous Year)	(7.03)	(118.86)	(-)	(1.28)	(-)	(-)	(-)	(-)	(-)	(-)
Services Render	--	19.95	--	3.10	--	--	--	--	--	--
(Previous Year)	(-)	(-)	(-)	(1.80)	(-)	(-)	(-)	(-)	(-)	(-)
Rent Paid	--	1.20	--	--	--	--	--	--	--	--
(Previous Year)	(-)	(1.20)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Remuneration Paid	--	--	--	--	--	--	15.33	4.88	3.45	--
(Previous Year)	(-)	(-)	(-)	(-)	(-)	(-)	(17.280)	(4.88)	(3.45)	--
Closing Bal Receivable/ (Payable) by way										
Security Dep.	120.00	300.00	--	--	--	--	--	--	--	--
(Previous Year)	(120.00)	(300.00)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
Others	2.32	472.20	(5.67)	1.60	0.62	(44.40)	(173.48)	(54.29)	(0.52)	(22.50)
(Previous Year)	(22.36)	(269.54)	(11.46)	(6.71)	(-)	(7.65)	(262.79)	(46.79)	(0.52)	(2.50)

2.46 The Revised Schedule VI has become effective from April 01, 2011 for the preparation of financial statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous year's figures have been regrouped and rearranged reclassified wherever necessary to correspond with the current year's classification/disclosure.

As per our Report of even date attached
For Mayur Chokshi & Co
Chartered Accountants

For and on behalf of the Board of Directors

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
(Membership No.33936)
Mumbai - 10th July, 2012

Jayesh P. Choksi
Chairman &
Managing Director

Dr Sharat Gandhi
Director

Prakash Khulbe
Company Secretary

Mumbai - 10th July, 2012

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

I. Registration details

Registration No.	33519	State Code	11
Balance Sheet Date	31.03.2012	Registration Date	23.07.1984

II. Capital raised during the year (₹ in Lacs)

Public Issue	Nil	Right Issue	Nil
Bonus Issue	Nil	Private Placement	Nil

III. Position of mobilisation and deployment of funds (₹ in Lacs)

Total Liabilities	7412.78	Total Assets	7412.78
Sources of Funds			
Paid Up Capital	773.50	Reserves and Surplus	1177.92
Non Current Liability	874.53	Current Liability	4586.83
Application of funds			
Non Current Assets	2432.55	Current Assets	4980.23
Net Current Assets	--	Deferred Tax Liability	--
Misc. Expenditure	--	Accumulated Losses	--

IV. Performance of company (₹ In Lacs)

Total Income	8393.28	Total Expenditure	8096.27
Profit Before Tax	297.01	Profit After Tax	152.71
Earning Per Share in ₹.	0.20	Dividend Rate %	5

V. Generic Names of Three Principal Products / Services Of the Company (As per monetary Terms)

Item Code No. (ITC Code)	Product and Description
300490.01	Ayurvedic Medicine
294200.90	Bulk Drug-Lidocaine
560110.00	Sanitary Napkins

As per our Report of even date attached

For Mayur Chokshi & Co
Chartered Accountants

For and on behalf of the Board of Directors

Mayur Chokshi
Proprietor
Firm Registration No. 106116W
(Membership No.33936)
Mumbai - 10th July, 2012

Jayesh P. Choksi
Chairman &
Managing Director

Dr Sharat Gandhi
Director

Prakash Khulbe
Company Secretary

Mumbai - 10th July, 2012



RelieveTM Relax &

ANTI-STRESS
TABLETS

**Stress off...
toh life full on**




GUFIC
BIOSCIENCES LIMITED

Regd. Off.: Subhash Rd.-A, Vile Parle (E), Mumbai - 400 057. (INDIA)

Corp. Office: 2nd & 3rd floor, Old Sanskar Jyot School Bldg., (Above Bank of Maharashtra)
S.V. Road, Andheri (West), Mumbai 400 058. (INDIA)

Tel.: (91-22) 67261000 | Fax : (91-22) 67261068 | Email : gufic@guficbio.com | www.guficbio.com